Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dan Gralnek

Urology Madison, WI Medical Doctor

NPI 1811995319 CMS profile 500570

600 Highland Ave, Madison, WI 53792

Open in the dashboard

General payments

$141,573

196 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dan Gralnek of Madison, WI is reported in the CMS Open Payments database as having received $141,573 across 196 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $65,507 68
2024 General $20,580 43
2023 General $42,931 57
2022 General $11,272 17
2021 General $82 2
2019 General $1,201 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dan Gralnek
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Dan Gralnek were reported at $65,507. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Dan Gralnek Urology median Middle half National median
2019 $1,201 $480 $147–$1,201 $163
2020 $0 $246 $87–$645 $114
2021 $82 $358 $111–$1,000 $132
2022 $11,272 $476 $143–$1,263 $149
2023 $42,931 $560 $168–$1,461 $160
2024 $20,580 $563 $170–$1,464 $164
2025 $65,507 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $135,639 171 payments
  2. Richard Wolf Medical Instruments Corp. $3,613 4 payments
  3. Teleflex LLC $1,682 13 payments
  4. PROCEPT BioRobotics Corporation $310 5 payments
  5. Stryker Corporation $166 1 payment
  6. Cook Medical LLC $153 1 payment
  7. Astellas Pharma US Inc $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $117,931 66 payments
  2. Travel and Lodging $13,411 56 payments
  3. Food and Beverage $5,931 66 payments
  4. Consulting Fee $3,550 7 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $750 1 payment
Products named General payments · program years 2019–2025
  1. Lumenis Pulse 120H $65,333 84 payments
  2. Lumenis Pulse 50H $15,978 4 payments
  3. General - BPH $14,373 13 payments
  4. GreenLight XPS $8,312 7 payments
  5. General - Kidney Stone Disease $8,190 7 payments
  6. Moses $2,515 8 payments
  7. UROLIFT $1,664 12 payments
  8. Moses 550 D\F\L $1,186 8 payments
  9. General BPH $758 4 payments
  10. GENERAL KIDNEY STONE DISEASE $396 3 payments
  11. Other $1,424 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

798

Median for Urology: 1,053

Drug cost

$81,432

Median for Urology: $101,464

Branded share of claims

34%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 101 $56,573
Testosterone Generic 60 $11,147
Tamsulosin Hcl Generic 217 $3,426
Methenamine Hippurate Generic 44 $2,714
Oxybutynin Chloride Er Oxybutynin Chloride Brand 122 $2,328
Testosterone Cypionate Generic 23 $1,365
Finasteride Generic 56 $819
Tolterodine Tartrate Er Tolterodine Tartrate Brand 13 $743
Alfuzosin Hcl Er Alfuzosin Hcl Brand 24 $664
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 11 $367

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$79,163

Medicare's payments for the services billed

Medicare patients

391

Average age 74

Services billed

782

30 women, 361 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 34%
Diabetes 27%
Chronic kidney disease 26%
Cancer 26%
Ischemic heart disease 24%
Atrial fibrillation 19%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

196 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record